Acquisition Announced
Eli Lilly and Company acquisition of Orna Therapeutics
US$2.4bn consideration
Announced 9 Feb 2026
Advisers
Orna Therapeutics
Target
- Financial adviser
- Legal adviser
- Goodwin

Team: Stuart Cable, Danielle Lauzon, Felipe M. Heiderich, Wei Xu, Evan Lee, Andrea Akinbola, Daniela Sanchez, Belem Sanchez, Artimus Cunningham, Christian Fan, Catherine McCarty, Carl Morales, Michael Shuster, Christopher Haley, Pavel Puzerey, Nancy Urizar, Frank Qin, Sarah Bock, James Oh, Christina Lewis, Daniel Karelitz, Susan Lee, Justin Pierce, GG Guckaya, Arman Oruc, Simone Waterbury, Scott Zilora, Abby King
Eli Lilly and Company
Acquirer
Other advisers
- Financial adviser
- Target
- Orna Therapeutics
- Acquirer
- Eli Lilly and Company
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Pharma
In the league tables
Similar deals
- Servier acquisition of Day One Biopharmaceuticals Mar 2026 · US$2.5bn · Biotech
- Sanofi acquisition of Dynavax Technologies Dec 2025 · US$2.2bn · Biotech
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- Fresenius acquisition of mAbxience Oct 2026 · US$1.9bn · Biotech
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
Sources
- 9 Feb 2026 Goodwin Advises Orna Therapeutics in Acquisition by Eli Lilly for Up to $2.4 Billion goodwinlaw.com
- 9 Feb 2026 Eli Lilly to Acquire Orna Therapeutics paulweiss.com
- 9 Feb 2026 Press release (PR Newswire), Lilly to acquire Orna Therapeutics to advance cell therapies prnewswire.com
- 19 May 2026 Lazard: UNITED STATES Lilly to Acquire Orna Therapeutics to Advance Cell Therapies lazard.com

